Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine as an adjunct for pain in sickle cell crisis
NCT03502421Phase 3Withdrawn
- Sponsor
- University of South Florida
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of ketamine in sickle cell disease (SCD) (2 arms), sponsored by University of South Florida. Primary endpoints: Total opioid use in milligrams morphine equivalents and Pain scores measured on the Visual Analog Scale. Planned start Sep 2018; status: withdrawn.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03502421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502421.